Dr. Gabrail Nashat
Claim this profileGabrail Cancer Center Research
Area of expertise
Pancreatic Adenocarcinoma
Gabrail Nashat has run 1 trial for Pancreatic Adenocarcinoma. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Gabrail Nashat has run 1 trial for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Gabrail Cancer Center Research
Gabrail Cancer Center
Clinical Trials Gabrail Nashat is currently running
Fianlimab + Cemiplimab
for Non-Small Cell Lung Cancer
This trial is testing a new drug combination for patients with advanced lung cancer. It aims to see if using two drugs together is more effective than one alone. The study also looks at side effects, how the drugs are processed in the body, and their impact on quality of life.
Recruiting
0 awards
Phase 2 & 3
CB-03-10
for Advanced Cancers
Subjects will undergo baseline evaluation and an assessment of extent of disease. Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a modified Fibonacci schema using a standard oncology 3+3 study design to define an MTD and a RP2D. Plasma PK samples will be collected at predetermined timepoints for all subjects. Subjects in Part 2 (Dose Expansion) of the study will receive CB-03-10 at the RP2D determined in the Part 1 of the study. The indications included in each group will be determined at the completion of Part 1 of the study by Safety Review Committee (SRC). Subjects will be evaluated weekly initially (for 2 cycles in Part 1 and for 1 cycle in Part 2) and every 2 weeks thereafter. Reassessment of disease will be conducted at Week 8 and every 8 weeks thereafter. Subjects with evidence of response (partial or complete) will be re-evaluated at least 4 weeks later for confirmation.
Recruiting
1 award
Phase < 1
9 criteria
More about Gabrail Nashat
Clinical Trial Related
2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Gabrail Nashat has experience with
- Cemiplimab
- Fianlimab
- Gemcitabine
- Nab Paclitaxel
- NovoTTF-100L(P)
- NovoTTF-200T
Breakdown of trials Gabrail Nashat has run
Pancreatic Adenocarcinoma
Non-Small Cell Lung Cancer
Prostate Cancer
Solid Tumors
CB-03-10
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gabrail Nashat specialize in?
Gabrail Nashat focuses on Pancreatic Adenocarcinoma and Non-Small Cell Lung Cancer. In particular, much of their work with Pancreatic Adenocarcinoma has involved Stage III patients, or patients who are undergoing treatment.
Is Gabrail Nashat currently recruiting for clinical trials?
Yes, Gabrail Nashat is currently recruiting for 3 clinical trials in Canton Ohio. If you're interested in participating, you should apply.
Are there any treatments that Gabrail Nashat has studied deeply?
Yes, Gabrail Nashat has studied treatments such as Cemiplimab, Fianlimab, Gemcitabine.
What is the best way to schedule an appointment with Gabrail Nashat?
Apply for one of the trials that Gabrail Nashat is conducting.
What is the office address of Gabrail Nashat?
The office of Gabrail Nashat is located at: Gabrail Cancer Center Research, Canton, Ohio 44718 United States. This is the address for their practice at the Gabrail Cancer Center Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.